VENUSCANCER
Financiado
Women s cancers do variations in patterns of care explain the world wide inequa...
Women s cancers do variations in patterns of care explain the world wide inequalities in survival and avoidable premature deaths?
Opening the World Cancer Congress in Paris in November 2016, President François Hollande insisted that women should be at the heart of cancer control, because they are victims of inequality in access to prevention, treatment and s...
Opening the World Cancer Congress in Paris in November 2016, President François Hollande insisted that women should be at the heart of cancer control, because they are victims of inequality in access to prevention, treatment and screening in every country in the world.
Breast, ovarian and cervical cancers are a major public health problem world-wide. Each year, approximately 2.5 million women are diagnosed with one of these cancers, and 900,000 women die from them, mainly in low- and middle-income countries.
The CONCORD programme for global surveillance of cancer survival reported striking differences in survival from these three cancers. Population-based cancer survival is a key measure of the overall effectiveness of health systems in dealing with cancer, from early diagnosis to comprehensive investigation and optimal treatment. I will exploit the CONCORD data base, as follows:
• Access primary medical records in selected high- and low-income countries to collect more detailed data on stage at diagnosis, staging investigations, morphology, grade, prognostic bio-markers and treatment, for the most recent year during 2010-2014 for which data are available
• Analyse the distributions of stage and treatment (patterns of care)
• Estimate 1- and 5-year survival trends by stage, histological group and/or molecular subtype
• Quantify inequalities in survival as the number of premature deaths that would be avoidable if survival in a given country (region) were equal to that in a neighbouring country with higher survival.
This ground-breaking work will show that it is possible (a) to collect high-quality, complete clinical information at population level even in low- and middle-income countries; (b) to explain the striking inequalities in women’s cancer survival world-wide, and (c) to summarise these inequalities in a single number (avoidable deaths) as a powerful tool that motivates policymakers to reduce inequalities in survival.
ver más
Duración del proyecto: 85 meses
Fecha Inicio: 2018-03-28
Fecha Fin: 2025-04-30
Fecha Fin: 2025-04-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2018-03-28
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2017-COG:
ERC Consolidator Grant
Cerrada
hace 7 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICIN...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
679.74K€ |
Participante